Structure of dolichol metabolites and their tissue and subcellular distribution {#Sec1}
===============================================================================

Polyisoprenoid alcohols are membrane lipids present in every cell, from archaea to higher eukaryotes. They all have in common a function as sugar carrier for protein glycosylation but display a surprising structural diversity between different species and also inside the same organism (Swiezewska and Danikiewicz [@CR52]; Jones et al. [@CR25]). The most common species, dolichol was originally identified by Pennock, Hemming and Morton in 1960 (Pennock et al. [@CR36]). Dolichol phosphate requirement for glycoprotein biosynthesis was established 10 years later by Behrens and Leloir (Behrens and Leloir [@CR2]). During dolichol biosynthesis, isoprenoids are used as a five-carbon building block to generate linear polymers. These polyisoprenoids are not present as species of a single chain length, but are found as a mixture (or family) of four or more different chain lengths, with one or two chain lengths predominating. The size of dolichols (i.e., the mixture of different chain lengths) is variable depending on the species. In the yeast *S.cerevisiae*, the size ranges from 14 repeating isoprene units to 18 (Dol-14 to Dol-18) and the major dolichols are Dol-16 and Dol-17. A preponderance of Dol-19 has been observed for several vertebrates including human (Chojnacki and Dallner [@CR7]).

Whereas the length of these lipids is variable, the configuration of the double bonds of polyisoprenoids is fixed. All dolichol species characterized so far show a di-trans, poly-cis configuration. This is a consequence of the involvement of two types of enzyme, a short-chain trans-prenyl transferase and a long-chain cis-prenyl transferase (Skorupinska-Tudek et al. [@CR50]). The α-terminal isoprene unit is unsaturated in polyprenol (formerly dehydrodolichol), whereas dolichol contains a saturated α-terminal unit (See Fig. [2](#Fig2){ref-type="fig"}). This saturation event is of great interest because it is absent in bacteria but required in many eukaryotic cells (Krag [@CR29]). The terminal hydroxyl group of dolichol may exist either free, phosphorylated or esterified with fatty acids. Depending on the tissue or membrane, dolichyl esters represent 10 to 60% of the total dolichol content and Dol-P in general represents less than 10% (Tollbom and Dallner [@CR54]).

Dolichol biosynthesis is known to occur mainly on the cytoplasmic face of the ER, where N*-*glycosylation occurs. Besides the presence of glycosylated dolichol species in the ER, dolichol is present in all subcellular membrane systems. The free alcohol, but also phosphorylated and esterified dolichol are detected in peroxisomes and are highly enriched in lysosomes, plasma membrane and Golgi vesicles (Rip et al. [@CR38]). The ER microsomal fraction is low in dolichol compared to other organelles. The mitochondrial membranes and nuclei also contain a limited amount of dolichol, especially low in the mitochondrial inner membrane.

All tissues and almost all membranes in eukaryotic cells contain dolichol. In general, they are present in small absolute quantities, only a few percent compared to glycerol-based phospholipids (Chojnacki and Dallner [@CR7]). However, the amount is highly variable depending on tissue and age (Rip et al. [@CR39]). For example, in human endocrine tissues, this lipid is present in milligram quantities per gram of wet weight, as much as phospholipids. In different species, several organs are highly enriched in dolichol. In human, testes and especially pituitary are associated with high contents of dolichol. Surprisingly, human tissues seem to have levels 5 to 10-fold higher in comparison to the corresponding tissues from rat or mouse, ranging from \~ 0.1-2 mg/g fresh weight in human versus \~ 10-200 μg/g in mouse or rat (Rip and Carroll [@CR37]). Dolichol is also detected in the serum at low concentration, associated with the HDL fraction (Elmberger et al. [@CR12]).

The reason of the specific enrichment of some tissues versus others is unknown, but does not seem to be correlated with the level of glycosylation.

A significant age-related accumulation of dolichol has been reported. In the human brain, a 100-fold increase has been detected during the aging process (Pallottini et al. [@CR35]), a similar increase has been observed in other tissues. These accumulations might also be involved in pathology as elevated dolichol levels have been detected in hepatocarcinogenesis and ceroid lipofuscinosis (Ericsson et al. [@CR13]). However, this accumulation seems to be disrupted in Alzheimer's disease as a significant reduction of dolichol levels has been detected in patient brains (Edlund et al. [@CR10]).

Cellular functions of dolichol {#Sec2}
==============================

Phosphorylated dolichol has a well defined role as a lipid carrier for the glycan precursor in the early stages of N-linked protein glycosylation. This precursor is assembled in the endoplasmic reticulum of all eukaryotic cells (Fig. [1](#Fig1){ref-type="fig"}). During N-linked protein glycosylation, a first dolichol phosphate is used by the GlcNAc-1-phosphotransferase to start the assembly of the lipid-linked oligosaccharide (LLO) on the cytoplasmic face of the ER. The product of this reaction is elongated to Man~5~GlcNAc~2~-P-P-Dol and then flipped to the inside of the ER. Then four other dolichol phosphates, previously linked to a mannose (Man-P-Dol) and flipped inside the ER lumen, are used as sugar donor for LLO synthesis. Finally, three dolichol phosphates in the form of dolichol phosphate glucose (Dol-P-Glc) as sugar donor are used for completion of the LLO before transfer of the glycan onto nascent proteins (Fig. [1](#Fig1){ref-type="fig"}). In addition to its role during LLO biosynthesis, Man-P-Dol is a necessary substrate for C- and O-mannosylation as well as GPI anchor biosynthesis (Rosenwald et al. [@CR41]). Fig. 1Dolichol cycle in the endoplasmic reticulum in human. The Dol-P pool available for glycosylation reactions originates from de novo synthesis of dolichol phosphate and its recycling from the lumenal leaflet to the cytoplasmic leaflet of the ER. Cellular functions of dolichol are indicated including known functions in N-glycosylation (1--2), O-mannosylation (3), GPI-anchor biosynthesis (4) and suspected effects on membrane biophysical properties (5--6). Abbreviations: FPP, farnesyl pyrophosphate; DHDDS, dehydrodolichyl diphosphate synthase; SRD5A3, steroid 5-alpha reductase 3; DOLK, dolichol kinase; DPM1-3, dolichyl-phosphate mannosyltransferase polypeptide 1--3; MDPU1, mannose-P-dolichol utilization defect 1; ALG5, asparagine-linked glycosylation 5; DOLPP1, dolichyl pyrophosphate phosphatase 1; LLO, lipid-linked oligosaccharide

In comparison to dolichol phosphate, the role of the free alcohol and its carboxylic ester is less established. An important question is the effect of these lipids on the physical properties of biological membranes. Biophysical studies have shown that dolichol and dolichol phosphates destabilize the bilayer structure of model membranes, and also increase their fluidity (Valtersson et al. [@CR57]). Isolated membrane phospholipids may adopt different phases including the lamellar bilayer phase and a phase where phospholipids are arranged as cylinders with the lipid head group facing the inner core of the cylinder, also called hexagonal phase II (Turned and Gruner [@CR55]). Dolichol promotes this hexagonal phase II organization, which may facilitate movements between the two layers of the membrane and may elicit the transmembrane movement of LLOs. This property would add another function for this lipid in the glycosylation process. Another interesting property is the fact that dolichol enhances vesicle fusion and that dolichol phosphate stimulates the fusion of rat liver microsomes (van Duijn et al. [@CR59]). In this way, dolichol might play a more general role in membrane trafficking. In vivo, consequences of dolichol synthesis defects have been investigated in a yeast mutant for the *cis*-isoprenyltransferase (*cis*-IPTases) *RER2* responsible for the elongation of the polyisoprenoid chain (Sato et al. [@CR46]) (Belgareh-Touze et al. [@CR3]). These studies suggest that free dolichol is involved in vesicle trafficking, a function in agreement with an enrichment of the Golgi apparatus for this lipid.

A specific role for the dolichol-ester has not been clearly established. Besides an effect on membrane properties, the esterified form was suggested to be necessary for intracellular dolichol transport (Tollbom and Dallner [@CR54]; Turunen and Schedin-Weiss [@CR56]). An oxidized derivative of dolichol, dolichoic acid has also been identified in human brain (Ward et al. [@CR62]). It is speculated to result from dolichol catabolism (Van Houte et al. [@CR60]), but its exact function is unknown.

De novo synthesis of dolichol and recycling {#Sec3}
===========================================

The first steps in the biosynthesis of dolichol are common with those for cholesterol and belong to the mevalonate pathway (Fig. [2](#Fig2){ref-type="fig"}). This pathway starts with the condensation of acetyl-CoA, followed by the production of mevalonate through the action of HMG-CoA reductase (Swiezewska and Danikiewicz [@CR52]). After several modifications, isopentenyl pyrophosphate (IPP) is produced. IPP condensation gives rise to farnesyl pyrophosphate (FPP), used as the substrate of many reactions including the synthesis of cholesterol, dolichol, solanesyl pyrophosphate (i.e., the side chain of ubiquinone) and for isoprenylation of proteins. Fig. 2De novo biosynthesis of dolichol phosphate in human. Polyisoprenoids are generated by the condensation of isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP), the 5-carbon building blocks of all isoprenoids. The mevalonate pathway is responsible for the synthesis of IPP and DMAPP. The first step dedicated to dolichol biosynthesis is the elongation of farnesyl pyrophosphate by the dehydrodolichyl diphosphate synthase (DHDDS) . This cis-prenyl transferase uses IPP as substrates to produce polyprenol pyrophosphate. It is believe that this polyprenol pyrophosphate is then dephosphorylated into polyprenol before its reduction by SRD5A5. Finally, the dolichol kinase (DOLK) transfers a phosphate from CTP to dolichol

Elongation step {#Sec4}
---------------

*Cis*-IPTases catalyse the synthesis of polyprenol pyrophosphate by sequential head-to-tail *cis* addition of multiple molecules of IPP to farnesyl pyrophosphate (FPP). This is the first step dedicated to dolichol synthesis and takes place on the cytoplamic side of the ER. At least two enzymes are involved in this process in yeast (i.e., *RER2* and *SRT1*). In mammals only one *cis*-IPTase has been characterized (Shridas et al. [@CR49]). However, some other uncharacterized or partially characterized enzymes might be involved. For example, the human protein NUS1, homolog of the yeast nuclear undecaprenyl pyrophosphate synthase 1, shares significant sequence homologies with *cis*-IPTs. Structural analysis of these enzymes (Takahashi and Koyama [@CR53]) as well as functional studies in yeast (Sato et al. [@CR46]) indicate that *cis*-IPTs themselves determine the chain length of their products. This was illustrated in a recent study from Rush et al. (Rush et al. [@CR44]) where the yeast *cis*-IPTase was replaced by a bacterial one, resulting in the synthesis of a dolichol with the length of the bacterial polyisoprenoid (i.e., 11 units instead of 14--18 units). An intriguing aspect of these *cis*-IPTases is the absence of a predicted transmembrane domain in their sequence despite their ER localization. This might be explained by the existence of unknown membrane protein interactors.

Dephosphorylation step {#Sec5}
----------------------

This step is supposed to occur between the elongation process and the reduction step. Polyprenol pyrophosphate phosphatase and polyprenol phosphatase activities have been reported in whole-cell homogenates (Wolf et al. [@CR63]), however, the molecular basis supporting these enzymatic reactions is unknown. A dolichol pyrophosphate phosphatase has been identified in yeast (*CWH8*) (Fernandez et al. [@CR14]). This enzyme is involved in the recycling of dolichol after oligosaccharide transfer to a protein, by removing one phosphate from Dol-PP in the ER (Fig. [1](#Fig1){ref-type="fig"}). This recycling of dolichol phosphate plays a major role in the regulation of the dolichol phosphate pool available for the different glycosylation pathways (Schenk et al. [@CR47]).

An alternative hypothesis suggests that the terminal event of the elongation process could be the condensation of a molecule of isopentenol instead of IPP (Ekstrom et al. [@CR11]), avoiding a final dephosphorylation and reduction event.

Reduction step {#Sec6}
--------------

Several mutant cell lines defective for this step have been identified, including Chinese hamster ovary cell (CHO) mutants belonging to the same complementation group lec9. They were identified based on lectin resistance and present a general hypoglycosylation of proteins associated with a reduced amount of mature LLO (Rosenwald and Krag [@CR40]). These mutants show a similar phenotype with an accumulation of polyprenols of a chain length identical to dolichols usually present in these cells, but lacking the saturation of the alpha-isoprene unit. Polyprenols are obligatory intermediates for the synthesis of dolichols and are detected in large amount during in vitro biosynthesis of dolichol. However, in vivo, polyprenol levels are usually very low, often undetectable (Ekstrom et al. [@CR11]; Sagami et al. [@CR45]), probably the result of a fast conversion to dolichols. A mutant cell line from *Trypanosoma Brucei* shows similar biochemical defects including the hypoglycosylation of proteins and the accumulation of polyprenol (Acosta-Serrano et al. [@CR1]). These CHO and Trypanosoma mutants have in common a defect only partial in dolichol biosynthesis, still present in these cells, and an unknown genetic basis for this defect.

We reported recently the identification of the first enzyme associated with this reduction step. This enzyme, SRD5A3 in human and DFG10 in *S.cerevisiae*, shows homology with steroid 5-alpha reductase enzymes (Cantagrel et al. [@CR4]). Mutation in the corresponding genes results in a partial block of dolichol biosynthesis with an accumulation of polyprenol and hypoglycosylation of proteins. Human *SRD5A3* can correct the phenotype of the yeast deleted for *DFG10* by preventing the accumulation of polyprenols and the hypoglycosylation of carboxypeptidase Y (CPY). Mutations associated with this defect in human are mostly homozygous early truncating mutations, resulting in some cases in non-sense mediated mRNA decay. These observations suggest that null alleles are responsible for this condition. In yeast, the d*fg10* deletion mutant is also only partially blocked in this reduction step with an important decrease in dolichol (i.e., a 70% decrease was detected (Cantagrel et al. [@CR4])) associated with polyprenol accumulation. These results reveal an unexpected alternative pathway for dolichol synthesis, probably conserved from yeast to human. The identification of these *SRD5A3/DFG10* genes may be a starting point to look for physical and genetic interactors in order to understand better the coupling of this reduction step with polyprenol pyrophosphate elongation and dephosphorylation as well as the nature of the alternative pathway involved in the polyprenol reduction step.

Phosphorylation step {#Sec7}
--------------------

The availability of dolichol phosphate is one of the rate-limiting factors controlling the synthesis of LLOs in eukaryotic cells (Carson et al. [@CR5]; Spiro and Spiro [@CR51]). Dolichol Kinase (DOLK) is a CTP-dependent enzyme localized in the ER with a catalytic site oriented to the cytoplasmic side of the ER (Shridas and Waechter [@CR48]). The yeast gene encoding for the dolichol kinase is essential, the phenotype resulting from a mutation of this gene was studied with the temperature sensitive mutant *sec59* (Heller et al. [@CR19]). In this mutant, Dol-P levels are less than 10% of wt yeast at restrictive temperature. This reduced availability of Dol-P results in incomplete glycosylation of secretory proteins and strongly affects O-mannosylation and GPI anchor synthesis (Heller et al. [@CR19]).

Dolichol recycling {#Sec8}
------------------

After the transfer of the oligosaccharide to nascent proteins, Dol-P-P is released in the lumenal leaflet of the ER (Fig.[1](#Fig1){ref-type="fig"}). After one dephosphorylation step mediated by DOLPP1, Dol-P returns directly to the cytoplasmic leaflet where it can be re-used for LLO biosynthesis (Rush et al. [@CR43]). The human *DOLPP1* gene is the predicted ortholog of the *CWH8/CAX4* yeast gene. The functional conservation through evolution was tested with the mouse gene *Dolpp1* (Rush et al. [@CR42]). In yeast, a defect in recycling Dol-P-P from the lumenal to the cytoplasmic leaflet of the ER impairs protein N-linked glycosylation (van Berkel et al. [@CR58]; Fernandez et al. [@CR14]). This indicates that this recycling of Dol-P-P contributes significantly to the pool of Dol-P available for glycosylation reactions.

Human disorders affecting the dolichol cycle {#Sec9}
============================================

Phenotypes resulting from dolichol biosynthesis defects {#Sec10}
-------------------------------------------------------

Defects in the biosynthesis of N-glycans lead to diseases known as congenital disorders of glycosylation (CDG) (Freeze [@CR15]; Jaeken and Matthijs [@CR22]; Haeuptle and Hennet [@CR18]). Research on CDG increases our understanding of consequences of a defect in the dolichol cycle. Recently, several diseases resulting from defects in dolichol biosynthesis (SRD5A3, DOLK) have been described, whereas other defects are closely associated with dolichol metabolism (MPDU1, DPM synthase). Unlike the disruption of genes strictly involved in the N-glycosylation process, defects in dolichol metabolism are predicted to affect several cellular pathways (Denecke and Kranz [@CR8]).

Recently, the most upstream defect in the mevalonate pathway for dolichol-P synthesis was identified, it affects the reduction of polyprenol to dolichol. In a group of patients with variable eye malformations, cerebellar vermis hypoplasia, anemia, ichthyosiform dermatitis, liver dysfunction and coagulation abnormalities, we recently identified loss of function mutations in the *SRD5A3* gene (SRD5A3-CDG; CDG-Iq) (Cantagrel et al. [@CR4]; Morava et al. [@CR34]). The 12 patients originally reported have an abnormal N-glycosylation profile of serum transferrin consistent with a role of polyprenol reductase in N-glycosylation. The transferrin isoelectric focusing shows a CDG type I profile with increased levels of asialo- and disialotransferrin. A family has also been reported without a clear diagnosis of CDG based on a routine transferrin test (Kahrizi et al. [@CR26]). This observation might be the result of variabilities sometimes observed in CDG patients (Vermees et al. [@CR61]) or might indicate that milder forms of this disorder can be missed with routine transferrin isoelectric focusing.

A deficiency one step further of dolichol kinase (MIM\#610768; DOLK-CDG; CDG-Im) was described in four children from two families who died in their 1^st^ year of life. Clinical features included dry ichthyosiform skin, seizures, severe muscular hypotonia, and progressive dilatative cardiomyopathy. The reported homozygous missense mutations almost abrogated the activity of the DOLK enzyme and were not able to complement the yeast dolichol kinase mutant (Kranz et al. [@CR31]). Severe defects in N-glycosylation have been demonstrated using IEF of transferrin but some aspects of the phenotype might be caused by the involvement of other pathways. It can be speculated that less severe mutations in the *DOLK* gene can be responsible for a milder phenotype.

Dolichol-P is subsequently converted into dolichol-P-mannose for use as mannose donor in different ER glycosylation reactions. Mutations in the Dol-P-Man utilization protein (MPDU1), required for the availability of Dol-P-Man in the ER, lead to CDG-If. Four patients have been described (Schenck et al. [@CR47]; Kranz et al. [@CR30]) with mutations in the *MPDU1* gene, presenting with early onset visual loss, seizures, psychomotor retardation and skin abnormalities like ichthyosyform skin. In all patients, N-glycosylation was found to be abnormal. Synthesis of Dol-P-Man is carried out by the DPM-synthase complex, consisting of DPM1-3 subunits. Mutations in DPM1 (CDG-Ie) were found in children with severe congenital visual loss, optic atrophy and seizures (Imbach et al. [@CR21]; Kim et al. [@CR28]), and one of the children was diagnosed with congenital frontal cortical hypoplasia (Garcia-Silva et al. [@CR17]). Although no muscle histology was reported, all patients presented with hypotonia and increased CK. The relatively mild DPM3 defect was characterized by muscle dystrophy and dilated cardiomyopathy. Immunohistochemical analysis indicated a defect in alpha-dystroglycan O-mannosylation (Lefeber et al. [@CR33]). No skin abnormalities were reported in the DPM synthase deficient patients.

Evidence for N-glycosylation defects {#Sec11}
------------------------------------

DOLK-CDG and SRD5A3-CDG have in common a clear defect in the ER part of the N-glycan biosynthesis (i.e., CDG type I). This defect is identified with the detection of glycoproteins with unoccupied N-glycosylation sites, both in patient serum and in the yeast models of these conditions. Multiple factors influence the variable site occupancy (Jones et al. [@CR24]) including substrate concentrations. The pathophysiology of dolichol kinase and polyprenol reductase deficiencies show overlapping features with a likely effect on the Dol-P pool although it is less clear for SRD5A3 defects.

DOLK deficiency impacts directly the pool of dolichol phosphate, thereby limiting protein N-linked glycosylation and other glycosylation pathways via reduced Dol-P-Man formation. It is interesting to note that only a special pool out of the total dolichol phosphate present in the ER membrane is thought to participate actively in the glycosylation process (Hubbard and Robbins [@CR20]; Gao and Lehrman [@CR16]).

SRD5A3 deficiency may have an indirect effect on the dolichol phosphate pool. In vitro, dolichol phosphate is the limiting factor of LLO synthesis in cell extracts form *SRD5A3* patient fibroblasts (Cantagrel et al. [@CR4]). Although only a small percentage of dolichol is converted to Dol-P, SRD5A3 may contribute directly to the dolichol pool available for phosphorylation and LLO biosynthesis. With respect to the minimal amount of dolichol in the ER, further research into organelle specific effects of dolichol cycle defects will be required to obtain further insights. In the case of polyprenol reductase deficiency there is a clear accumulation of polyprenol detected in yeast, mouse and to a lesser extend in the serum of *SRD5A3* patients. In these patients, serum levels of dolichols and polyprenols were elevated resulting in abnormal ratios of these lipids in favor of a block in the conversion of polyprenols to dolichol (Cantagrel et al. [@CR4]; Morava et al. [@CR34]). These serum polyisoprenoids are not available for protein glycosylation and they could result from regulation of cellular dolichol homeostasis. An intriguing question is if this accumulating precursor can have a deleterious effect on N-glycosylation or other cellular processes. In vitro studies indicate that sugar linked to polyprenol phosphate can be used by mammalian glycosyltransferases for LLO synthesis (D\'Souza-Schorey et al. [@CR9]), however, these substrates are not as effective as dolichol linked saccharides. It is not known if polyprenol can have an inhibitory effect on other dolichol-binding enzymes.

Evidence for O-mannosylation defects {#Sec12}
------------------------------------

O-mannosylation defects result in muscular dystrophy with elevated levels of creatine kinase and can be associated with varying degrees of cerebral cortex malformations, visual abnormalities and dilated cardiomyopathy. No muscular dystrophy has been detected in *SRD5A3* patients and creatine kinase levels were normal when tested. Brain imaging revealed cerebellar vermis hypoplasia as the main feature in *SRD5A3* patients whereas imaging of *DOLK* patients did not detect any malformations. A comparison with the MPDU1 and DPM disorders indicates that the muscular dystrophy and dilated cardiomyopathy could be shared between DOLK, DPM1 and DPM3, whereas these features are not present in SRD5A3 and MPDU1 defects.

For the neurological and visual problems, it is less clear how to correlate symptoms with pathophysiological pathways. Seizure are, for example, common in N-glycosylation and O-mannosylation defects, whereas deficiency of GPI anchor biosynthesis is associated with epilepsy as well (Krawitz et al. [@CR32]). Ophthalmological involvement is known for both N-glycosylation and O-mannosylation defects.

Clinical features resulting from other defects {#Sec13}
----------------------------------------------

The presence of skin involvement in SRD5A3 and DOLK deficiencies might reflect a specific function for dolichol/dolichol phosphate in normal skin development. It is interesting to note that MPDU1-CDG and not DPM1 or DPM3-CDG shows similar skin involvement, a feature uncommon for N-glycosylation and O-mannosylation defects. This could suggest that the MPDU1 protein is involved in dolichol/dolichol-P homeostasis as well.

Future therapeutic options for dolichol biosynthesis defects {#Sec14}
============================================================

The in vitro rescue experiment of the LLO synthesis defect in cell extracts from *SRD5A3* patients indicates that the adjustment of dolichol phosphate levels in patient cells could theoretically correct the *N-*glycosylation defect. Polyisoprenoid lipids are present in the diet, polyprenols are abundant in mature plants in contrast with animal tissues that possess dolichols. The contribution of dietary dolichol to the cellular pool of dolichol has been investigated in rat liver. An important part of the cholesterol utilized in metabolic processes is supplied by the diet but for polyisoprenoids, this contribution appeared to be quite limited. It was found that polyisoprenoids supplied orally were taken up through the rat gastrointestinal system; from 0.05% to a few percent of the total (Keller et al. [@CR27]; Jakobsson et al. [@CR23]). The uptake efficiency depends on the form of administration of dolichol and its incorporation into liposomes was found to be the most efficient. The study of the subcellular incorporation revealed that microsomes contain only a few percent of the labeled dietary dolichols. Making a significant part of this exogenous dolichol bioavailable will be an important step to consider some therapeutic options. Some previous studies detected that a fraction of dietary dolichol taken up by the liver was able to be phosphorylated (i.e., about 10% ) and potentially plays a role in protein glycosylation (Jakobsson et al. [@CR23]) (Chojnacki and Dallner [@CR6]).

Conclusion {#Sec15}
==========

Historically, mutations in genes encoding glycosyltransferases in the N-glycosylation process have been described as the cause of CDG. The identification of dolichol metabolism defects in patients with CDG opens a new field of metabolic diseases. They present unique opportunities to study the functional role of a poorly understood lipid, dolichol, in cellular processes. Besides its involvement in protein glycosylation via phosphorylation to dolichol-P in the ER, this will facilitate the identification of its role(s) in other organelles. Several steps involved in the synthesis, recycling and regulation of dolichol availability are still unknown. Exploration of these steps in humans might allow the identification of new inborn error of metabolisms in a spectrum overlapping partially with the Congenital Disorders of Glycosylation.
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